What is the recommended dose, dilution, and intravenous administration method of tranexamic acid for postpartum hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tranexamic Acid IV Administration for Postpartum Hemorrhage

Administer 1 gram of tranexamic acid (100 mg/mL concentration) intravenously at 1 mL/minute (infused over 10 minutes), with a second 1 gram dose if bleeding continues after 30 minutes or restarts within 24 hours of the first dose. 1

Critical Timing Window

The WHO strongly emphasizes that tranexamic acid must be given within 3 hours of birth to reduce mortality from bleeding. 1 This is not a soft recommendation—the evidence shows:

  • Benefit decreases by 10% for every 15-minute delay in administration 1
  • No benefit is seen after 3 hours, and administration beyond this window is suspected to be potentially harmful 1
  • Earlier administration increases benefit, so give it as soon as PPH is diagnosed 1

This timing evidence comes from individual participant data meta-analysis of over 40,000 bleeding patients from the WOMAN and CRASH-2 trials, making it highly robust. 1

Specific Dosing Protocol

First Dose

  • 1 gram (1000 mg) tranexamic acid
  • Concentration: 100 mg/mL (supplied as 10 mL vial)
  • Rate: 1 mL/minute = infusion over 10 minutes
  • Timing: As soon as PPH is clinically diagnosed 1

Second Dose (if needed)

  • 1 gram tranexamic acid, same concentration and rate
  • Give if:
    • Bleeding continues after 30 minutes from first dose, OR
    • Bleeding restarts within 24 hours of completing first dose 1

Dilution and Preparation

The FDA label for tranexamic acid indicates it may be mixed with most infusion solutions including electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. 2 However, the WHO guideline based on the WOMAN trial used a fixed concentration of 100 mg/mL administered at 1 mL/min. 1

Critical safety points:

  • DO NOT mix with blood 2
  • DO NOT mix with penicillin-containing solutions 2
  • FOR INTRAVENOUS USE ONLY—accidental intrathecal administration has caused maternal deaths from seizures and cardiac arrhythmias 2, 3
  • Infuse no faster than 1 mL/minute to avoid hypotension 2

Clinical Definition of PPH for Treatment

Tranexamic acid should be given for clinically diagnosed PPH, defined as:

  • Blood loss >500 mL after vaginal birth, OR
  • Blood loss >1000 mL after cesarean section, OR
  • Any blood loss sufficient to compromise hemodynamic stability 1

When to Use

Give tranexamic acid in ALL cases of PPH, regardless of cause:

  • Uterine atony
  • Genital tract trauma
  • Any other bleeding etiology 1

This represents a significant change from the 2012 WHO recommendation, which restricted use to cases where oxytocin and other treatments failed. The updated 2018 guideline broadened this based on the WOMAN trial showing mortality benefit across all PPH causes. 1

Integration with Standard PPH Management

Tranexamic acid is an adjunct to—not a replacement for—standard PPH management, which includes:

  • Fluid replacement
  • Uterotonics (oxytocin, etc.)
  • Vital sign monitoring
  • Non-surgical interventions (bimanual compression, balloon tamponade, etc.)
  • Surgical interventions if needed (brace sutures, arterial ligation, hysterectomy) 1

Use these interventions sequentially from least to most invasive while administering tranexamic acid early. 1

Contraindications

Avoid tranexamic acid in:

  • Known thromboembolic event during pregnancy
  • Active intravascular clotting
  • Subarachnoid hemorrhage (risk of cerebral edema and infarction) 1, 2

Common Pitfalls to Avoid

  1. Delaying administration: Every 15 minutes of delay reduces effectiveness by 10%. Don't wait for laboratory confirmation—clinical diagnosis is sufficient. 1

  2. Giving after 3 hours: This may be harmful rather than beneficial. 1

  3. Wrong route of administration: Intrathecal injection has caused maternal deaths. Ensure clear labeling and double-check route before administration. 2, 3

  4. Infusing too rapidly: Rates faster than 1 mL/minute can cause hypotension. 2

  5. Withholding based on bleeding etiology: Give for all PPH causes, not just when uterotonics fail. 1

Evidence Quality

The WHO guideline is based primarily on the WOMAN trial (>20,000 women across 21 countries), which demonstrated a 19% reduction in bleeding-related death when tranexamic acid was given within 3 hours. 1, 4 This represents the highest quality evidence available for PPH treatment and directly informs the dosing regimen recommended. 1

The evidence shows no increase in thromboembolic events with tranexamic acid use in PPH treatment. 1, 4, 5

References

4
Research

Tranexamic acid for post-partum haemorrhage: What, who and when.

Best practice & research. Clinical obstetrics & gynaecology, 2019

5
Research

Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2020

Related Questions

Can tranexamic acid (TXA) be continued three times a day for a few days if vaginal bleeding persists despite two initial doses?
Is tranexamic acid (TXA) contraindicated in a patient taking oral contraceptives (birth control)?
What is the dosage of Tranexamic acid (TXA) for uterine hemorrhage?
How long should oral Tranexamic Acid (TXA) be continued for a patient with spontaneous miscarriage and heavy vaginal bleeding?
Is tranexamic acid (tranexamic acid) indicated in a patient with suspected significant blood loss and hemodynamic instability due to an intrauterine miscarriage, presenting with hypotension (blood pressure 90/60), tachycardia (pulse rate 79), and normal oxygen saturation (SpO2 99%)?
In a postmenopausal woman, how long after stopping micronized progesterone does it take for hormone levels to return to postmenopausal values?
What is the appropriate management for elbow pain?
How do thalassemias cause anemia?
What antibiotic regimen is recommended for a penicillin‑allergic patient with suspected infected dry gangrene of the toe?
In a 63-year-old woman with chronic respiratory failure due to emphysema/COPD who underwent bilateral lung transplantation, is now extubated and receiving immunosuppressive and antibiotic therapy, and develops a progressive right chest tube air leak on postoperative day 8 with a persistent right pneumothorax on chest X‑ray, what is the next appropriate step: order chest CT, perform bronchoscopy, place an additional chest tube, or proceed to thoracotomy?
What levonorgestrel‑releasing intrauterine devices (LNG‑IUDs) are available for a 49‑year‑old woman with irregular menstrual bleeding who needs bleeding control and contraception?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question